Palogic Value Management raised its activist position in Health Catalyst to 7.1%, representing 5,374,949 common shares. For investors, the key distinction is the reported 13D activist intent, which identifies the position as activist rather than passive and places the fund’s increased ownership at the center of the disclosure.
Key Highlights
- Palogic Value Fund bought 174,617 Health Catalyst shares on 8/6/2026 at $1.76 per share.
- The reported stake includes 5,366,087 shares held by Palogic Value Fund and 8,862 shares in managed accounts.
- The 7.1% ownership calculation uses 75,256,381 Health Catalyst shares outstanding as of July 31, 2026.
The ownership figure is based on 75,256,381 Health Catalyst (NASDAQ: HCAT) shares outstanding as of July 31, 2026.
Palogic Holds 7.1% Stake
Palogic Value Fund, LP accounts for 5,366,087 shares of the position. Separately managed accounts add 8,862 shares, bringing the reported holding to 5,374,949 common shares. The stock is common stock with a Par Value of $0.001 per share. Palogic Value Fund purchased 174,617 shares on 8/6/2026 at $1.76 per share. It bought another 150,834 shares on 8/11/2026 at $1.70 per share and 11,332 shares on 8/17/2026 at $1.70 per share. Purchases continued with 1,003 shares on 8/18/2026 at $1.70 per share, followed by 1,000 shares on 8/19/2026 at $1.69 per share. The fund acquired 86,971 shares on 8/20/2026 at $1.66 per share and 19,260 shares on 8/21/2026 at $1.60 per share. Palogic Value Management also bought 716 shares on 9/1/2026 at $1.66 per share through managed accounts. The listed prices exclude commissions.
September Letter Addressed Board
A September 4 letter from Palogic Value Management to Health Catalyst’s board praised the completed VitalWare sale. The letter said the transaction had strengthened Health Catalyst’s financial position and moved the Business from a net-debt posture to a net-cash balance sheet. The letter also commended Health Catalyst employees and executive leadership.
FAQs
Q: What percentage of Health Catalyst does Palogic Value Management own?
A: Palogic Value Management owns 7.1% of Health Catalyst, representing 5,374,949 common shares. The position is reported with activist 13D intent.
Q: Is Palogic’s Health Catalyst position activist or passive?
A: Palogic’s Health Catalyst ownership is activist. The position is reported under Schedule 13D, distinguishing it from a passive Schedule 13G investment.
Q: What percentage of Health Catalyst does Palogic report owning?
A: Palogic reported holding 5,374,949 Health Catalyst common shares, including 5,366,087 held by Palogic Value Fund and 8,862 in separately managed accounts. That position represents 7.1% of shares outstanding.
Q: What prices did Palogic pay for its reported purchases?
A: The fund purchased shares at prices ranging from $1.60 to $1.76 per share across the listed August transactions. Palogic Value Management also bought 716 shares at $1.66 on September 1 through managed accounts.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.